Abbott Laboratories
ABTHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Abbott Laboratories (ABT) is listed under Medical Devices. At a $182.59B market cap, Abbott Laboratories ranks as a large-cap company within healthcare. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Market Cap
$182.59B
Beta
0.59
P/E (TTM)
34.15
P/E (Fwd)
17.40
EPS (TTM)
$3.09
EPS (Fwd)
$6.06
ROE
10.6%
ROA
5.3%
Cash
$5.60B
Total Debt
$32.72B
Free CF
$7.21B
52W Change
-16.3%
Annual Financials
Cash vs Debt
Where ABT stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, ABT finished 12.56% above its 150-day moving average ($99.92) and 6.46% above its 200-day moving average ($105.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABT overbought or oversold?
At the August 31, 2026 close, ABT's RSI(14) was 61.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ABT has $5.60B in cash with $32.72B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $7.21B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.6%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $43.65B (2022) to $44.33B (2025).
With a beta below 0.7, Abbott Laboratories typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ABT.